421 related articles for article (PubMed ID: 22490302)
1. Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
Emens LA; Silverstein SC; Khleif S; Marincola FM; Galon J
J Transl Med; 2012 Apr; 10():70. PubMed ID: 22490302
[TBL] [Abstract][Full Text] [Related]
2. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D; Ceccarelli M; Galluzzi L; Lu R; Palucka K; Samayoa J; Spranger S; Warren S; Wong KK; Ziv E; Chowell D; Coussens LM; De Carvalho DD; DeNardo DG; Galon J; Kaufman HL; Kirchhoff T; Lotze MT; Luke JJ; Minn AJ; Politi K; Shultz LD; Simon R; Thórsson V; Weidhaas JB; Ascierto ML; Ascierto PA; Barnes JM; Barsan V; Bommareddy PK; Bot A; Church SE; Ciliberto G; De Maria A; Draganov D; Ho WS; McGee HM; Monette A; Murphy JF; Nisticò P; Park W; Patel M; Quigley M; Radvanyi L; Raftopoulos H; Rudqvist NP; Snyder A; Sweis RF; Valpione S; Zappasodi R; Butterfield LH; Disis ML; Fox BA; Cesano A; Marincola FM;
J Immunother Cancer; 2019 May; 7(1):131. PubMed ID: 31113486
[TBL] [Abstract][Full Text] [Related]
3. Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.
Gulley JL; Repasky EA; Wood LS; Butterfield LH
J Immunother Cancer; 2017 Jul; 5(1):55. PubMed ID: 28716068
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy biomarkers 2016: overcoming the barriers.
Gulley JL; Berzofsky JA; Butler MO; Cesano A; Fox BA; Gnjatic S; Janetzki S; Kalavar S; Karanikas V; Khleif SN; Kirsch I; Lee PP; Maccalli C; Maecker H; Schlom J; Seliger B; Siebert J; Stroncek DF; Thurin M; Yuan J; Butterfield LH
J Immunother Cancer; 2017 Mar; 5(1):29. PubMed ID: 28653584
[TBL] [Abstract][Full Text] [Related]
5. Oncology meets immunology: the cancer-immunity cycle.
Chen DS; Mellman I
Immunity; 2013 Jul; 39(1):1-10. PubMed ID: 23890059
[TBL] [Abstract][Full Text] [Related]
6. Translation of cancer immunotherapy from the bench to the bedside.
Guo Q; Huang F; Goncalves C; Del Rincón SV; Miller WH
Adv Cancer Res; 2019; 143():1-62. PubMed ID: 31202357
[TBL] [Abstract][Full Text] [Related]
7. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
8. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
9. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
Anfray C; Ummarino A; Andón FT; Allavena P
Cells; 2019 Dec; 9(1):. PubMed ID: 31878087
[No Abstract] [Full Text] [Related]
10. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
Bule P; Aguiar SI; Aires-Da-Silva F; Dias JNR
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575965
[TBL] [Abstract][Full Text] [Related]
11. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Gnjatic S; Bronte V; Brunet LR; Butler MO; Disis ML; Galon J; Hakansson LG; Hanks BA; Karanikas V; Khleif SN; Kirkwood JM; Miller LD; Schendel DJ; Tanneau I; Wigginton JM; Butterfield LH
J Immunother Cancer; 2017; 5():44. PubMed ID: 28515944
[TBL] [Abstract][Full Text] [Related]
12. Shaping of an effective immune microenvironment to and by cancer cells.
Becht E; Goc J; Germain C; Giraldo NA; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
Cancer Immunol Immunother; 2014 Oct; 63(10):991-7. PubMed ID: 25112529
[TBL] [Abstract][Full Text] [Related]
13. Targeting the tumor microenvironment by immunotherapy: part 2.
Leibovici J; Itzhaki O; Huszar M; Sinai J
Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
[TBL] [Abstract][Full Text] [Related]
14. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment.
Capitani N; Patrussi L; Baldari CT
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681881
[TBL] [Abstract][Full Text] [Related]
15. Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression.
Laplagne C; Domagala M; Le Naour A; Quemerais C; Hamel D; Fournié JJ; Couderc B; Bousquet C; Ferrand A; Poupot M
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547627
[TBL] [Abstract][Full Text] [Related]
16. The Role of Tumor Microenvironment in Cancer Immunotherapy.
Frankel T; Lanfranca MP; Zou W
Adv Exp Med Biol; 2017; 1036():51-64. PubMed ID: 29275464
[TBL] [Abstract][Full Text] [Related]
17. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
[TBL] [Abstract][Full Text] [Related]
18. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
Ngambenjawong C; Gustafson HH; Pun SH
Adv Drug Deliv Rev; 2017 May; 114():206-221. PubMed ID: 28449873
[TBL] [Abstract][Full Text] [Related]
19. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.
Pérez-Romero K; Rodríguez RM; Amedei A; Barceló-Coblijn G; Lopez DH
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752264
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy: the art of targeting the tumor immune microenvironment.
da Silva JL; Dos Santos ALS; Nunes NCC; de Moraes Lino da Silva F; Ferreira CGM; de Melo AC
Cancer Chemother Pharmacol; 2019 Aug; 84(2):227-240. PubMed ID: 31240384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
